Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (5 of 5 Modules)

This activity provides an overview of recent data supporting the potential utility of circulating tumor DNA to predict risk and inform personalized therapeutic decision making for patients with lymphoma.

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL)

Activity Faculty

Roschewski, Mark-Faculty Headshot-135x135

Mark Roschewski, MD

Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Heslop, Helen-Faculty Headshot-135x135

[Q & A Panel] Helen E. Heslop, MD, DSc (Hon) (Chair)

Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Donovan, Katherine-Faculty Headshot-135x135

[Q & A Panel] Katherine Donovan, PhD

Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Meshinchi-Faculty Headshot_135x135

[Q & A Panel] Soheil Meshinchi, MD, PhD

Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources